Abstract:Qicen Yao, 1, * Qingchao Wu, 2, * Xiayu Xu, 1 Yixi Xing, 1 Jin Liang, 1 Qianqi Lin, 1 Meiqiong Huang, 1 Yiling Chen, 1 Bo Lin, 3 Weifei Chen 1 1 Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China; 2 Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Enshi, Hubei Province, People's Republic of China; 3 Department of Pharmacy, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, People's Republic of China *These authors contributed equally to this work Correspondence: Weifei Chen Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Boulevard, Haikou City, Hainan Province, People's Republic of China Email chenwf130@163.com Bo Lin Department of Pharmacy, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Boulevard, Haikou City, Hainan Province, People's Republic of China Email linbo13518072160@163.com Purpose: Resveratrol (Res) is a natural polyphenolic compound found in several plants and reported as a promising biological molecule with effective anti-fibrosis and anti-inflammatory activities. However, the underlying mechanism of Res on systemic sclerosis (SSc) remains unclear. In the study, we identified the key cellular signaling pathways involved in the Res regulatory process on SSc. Methods: Res-targeted genes interaction network was constructed using the STITCH database, and the shared Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways involved in both SSc and Res-targeted genes were then identified. The top five enriched KEGG pathways were visualized by GOplot. KEGG pathways associated with Res-targeted genes were established by Pathway Builder Tool 2.0. Quantitative real-time PCR (qRT-PCR) was used to assess the expression of sirtuin 1 (SIRT1), mammalian targeted of rapamycin (mTOR), and cytokines. Results: Enrichment analysis of Res-targeted genes showed 79 associated pathways, 27 of which were also involved in SSc. Particularly, SIRT1/mTOR signaling was found as one of the crucial regulatory pathways. In vitro results suggested that SIRT1-mediated mTOR degradation ameliorated bleomycin (BLM)-induced fibrosis and inflammation. Res was capable of elevating the SIRT1 level in fibroblasts and partially reversing mTOR-dependent induction of fibrosis and inflammation. Conclusion: These results indicated that Res is a feasible and effective choice for SSc and therapeutic target of mTOR could be a potential alternative for treatment of SSc. Keywords: resveratrol, systemic sclerosis, SIRT1, mTOR, signaling

Sirt1 Ameliorates Systemic Sclerosis by Targeting the Mtor Pathway.

Sirtuin1 Protects Against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.

MicroRNA-27a-3p Inhibits Lung and Skin Fibrosis of Systemic Sclerosis by Negatively Regulating SPP1.

Resveratrol Ameliorates Systemic Sclerosis via Suppression of Fibrosis and Inflammation Through Activation of SIRT1/mTOR Signaling

The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.

Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts

Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity

MiR-3606-3p Inhibits Systemic Sclerosis Through Targeting TGF-β Type II Receptor

Targeting CD13/aminopeptidase N as a novel therapeutic approach for scleroderma fibrosis

Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis

Ribosomal S6 protein kinase 2 aggravates process of systemic scleroderma.

Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis

SIRT1 Inhibits Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressiveness and Inflammatory Response Via Suppressing NF-κB Pathway

SIRT1 attenuates blood-spinal cord barrier disruption after spinal cord injury by deacetylating p66Shc

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis

Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis

Activation and Overexpression of Sirt1 Attenuates Lung Fibrosis Via P300

Mesenchymal Stem Cell Transplantation in Tight-Skin Mice Identifies Mir-151-5p As a Therapeutic Target for Systemic Sclerosis

Smad1 Pathway is Activated in Systemic Sclerosis Fibroblasts and is Targeted by Imatinib Mesylate.

IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis

RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis